Clinical Trials
81
Active:2
Completed:15
Trial Phases
5 Phases
Phase 1:4
Phase 2:3
Phase 3:1
+2 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (50 trials with phase data)• Click on a phase to view related trials
Not Applicable
41 (82.0%)Phase 1
4 (8.0%)Phase 2
3 (6.0%)Phase 3
1 (2.0%)Phase 4
1 (2.0%)Efficacy and Safety of Two Bladder-preserving Treatment Durations With Disitamab Vedotin Plus Toripalimab Combination in Her2-expressing Muscle-invasive Bladder Cancer: A Phase II, Open-Label, Randomized Clinical Trial
Not Applicable
Not yet recruiting
- Conditions
- Urology
- Interventions
- Drug: 6 cycle RC48 and JS001Drug: 12 cycle RC48 and JS001
- First Posted Date
- 2025-09-03
- Last Posted Date
- 2025-09-03
- Lead Sponsor
- Renmin Hospital of Wuhan University
- Target Recruit Count
- 60
- Registration Number
- NCT07151560
Digital Out-of-hospital Management on Clinical Outcomes in Patients With Early Cardiogenic Shock
Not Applicable
Recruiting
- Conditions
- ShockShock, Cardiogenic
- First Posted Date
- 2025-07-25
- Last Posted Date
- 2025-07-25
- Lead Sponsor
- Renmin Hospital of Wuhan University
- Target Recruit Count
- 472
- Registration Number
- NCT07085221
- Locations
- 🇨🇳
Renmin Hospital of Wuhan University, Wuhan, Hubei, China
Evaluation of Artificial Intelligence System in Diagnosis of Colorectal Tubular Adenoma Lesions
Recruiting
- Conditions
- Colorectal AdenomaArtificial Intelligence (AI) in Diagnosis
- First Posted Date
- 2025-07-18
- Last Posted Date
- 2025-07-18
- Lead Sponsor
- Renmin Hospital of Wuhan University
- Target Recruit Count
- 4200
- Registration Number
- NCT07073430
- Locations
- 🇨🇳
Renmin Hospital of Wuhan University, Wuhan, Hubei, China
The Efficacy and Safety of Treatment with Telitacicept in Antineutrophil Cytoplasmic Antibody-associated Nephritis (AAGN)
Phase 1
Active, not recruiting
- Conditions
- Antineutrophil Cytoplasmic Antibody (ANCA)-associated Nephritis (AAGN)
- Interventions
- First Posted Date
- 2024-10-24
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Renmin Hospital of Wuhan University
- Target Recruit Count
- 15
- Registration Number
- NCT06656962
- Locations
- 🇨🇳
Renmin hospital of Wuhan University, Wuhan, Hubei, China
The Efficacy and Safety of Treatment With Telitacicept in Primary Membranous Nephropathy
Phase 2
Not yet recruiting
- Conditions
- Primary Membranous Nephropathy
- Interventions
- First Posted Date
- 2024-09-26
- Last Posted Date
- 2024-09-26
- Lead Sponsor
- Renmin Hospital of Wuhan University
- Target Recruit Count
- 172
- Registration Number
- NCT06614985
- Locations
- 🇨🇳
Renmin Hospital of Wuhan university, Wuhan, Hubei China, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 16
- Next
News
Global Rheumatoid Arthritis Incidence Rises 13.2% Over Three Decades Despite Declining Mortality
Global rheumatoid arthritis incidence increased 13.2% from 1990 to 2021, affecting 17.9 million people worldwide by 2021, with significant regional disparities and a shift toward younger age groups.